Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex in Fabry Disease Neuropathic Pain
NCT04820361Unknown
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of cannabidiol in neuropathic pain (2 arms). Primary endpoint: Numerical Rating Scale at 28 days. Status: unknown.
02
Drugs
cannabidiol
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT04820361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04820361.